The 2 faces of ERK2 in MPNs.
(2022) Blood — Vol. 140, n° 4, p. 298-300 (2022)
Files
HavelangeandConstantinescuBlood2022.pdf
Open Access - Adobe PDF
- 854.42 KB
Details
- Authors
- Abstract
- (en) In this issue of Blood, Zhang et al1 reported that extracellular signal-regulated kinase 2 (ERK2) substrate-binding domains have opposing roles in Janus kinase 2 V617F (JAK2V617F)-driven myeloproliferative neoplasms (MPNs). One of the domains, ERK2-docking (ERK2-D), may be a promising therapeutic target for MPNs. Conversely, the other domain, ERK2-DEF–binding pocket (ERK2-DBP), blocks progression of the disease in a mouse model. This changes the perception that simply inhibiting the catalytic activity of ERK1/2 in MPNs would be an effective therapeutic strategy. [...]
- Affiliations
Citations
Havelange, V., & Constantinescu, S. (2022). The 2 faces of ERK2 in MPNs. Blood, 140(4), 298-300. https://doi.org/10.1182/blood.2022016536 (Original work published 2022)